Seasonal Allergic Conjunctivitis
4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Bausch + LombNJ - Bridgewater
2 programs2
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionPhase 31 trial
Loteprednol etabonate 0.2%Phase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NovartisKetotifen
Bausch + LombBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Bausch + LombLoteprednol etabonate 0.2%
Thea PharmaT1210
Clinical Trials (4)
Total enrollment: 758 patients across 4 trials
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
Start: Apr 2005Est. completion: Oct 2005229 patients
Phase 4Completed
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
Start: Nov 2022Est. completion: Aug 2023229 patients
Phase 3Completed
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
Start: Aug 2010Est. completion: May 2011300 patients
Phase 3Completed
Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis
Start: Apr 2011Est. completion: Feb 2012
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space